journal article·2022-01-26

Palladium Nanoplate-Based IL-6 Receptor Antagonists Ameliorate Cancer-Related Anemia and Simultaneously Inhibit Cancer Progression

Jianqiang Zhu, Qingfeng Fu, Shunhao Wang, Liting Ren, Wenya Feng, Shuting Wei, Zhihong Zhang, Yong Xu, Tomas Ganz, Sijin Liu

Nano Letters· Volume 22· Issue 2
Publisher page

Abstract

In recent years, targeted therapies and immunotherapeutics, along with conventional chemo- and radiotherapy, have greatly improved cancer treatments. Unfortunately, in cancer patients, anemia, either as a complication of cancer progression or as the result of cancer treatment, undermines the expected therapeutic efficacy. Here, we developed a smart nanosystem based on the palladium nanoplates (PdPLs) to deliver tocilizumab (TCZ, a widely used IL-6R antibody) to the liver for specific blockade of IL-6/IL-6R signaling to correct anemia. With chemical modifications, this nanosystem delivered a large mass of TCZ and enhanced liver delivery, inducing a marked suppression of hepcidin expression as a result of diminished IL-6 signaling. Through this mechanism, significant suppression of tumor progression was realized (at least in part) because of the corrected anemia after treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Erythropoietin and Anemia Treatment · Phagocytosis and Immune Regulation · PARP inhibition in cancer therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China

Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

University of Chinese Academy of Sciences, Beijing 100049, China

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States

Funding

Young Elite Scientists Sponsorship Program by Tianjin · National Natural Science Foundation of China · Tianjin Education Commission for Higher Education · Tianjin Research Program of Application Foundation and Advanced Technology

References (46)

Show source-provided references
1. 10.1159/00008312810.1159/000083128 ↗
2. 10.1111/j.1365-2362.2005.01527.x10.1111/j.1365-2362.2005.01527.x ↗
3. 10.1016/j.ejca.2004.06.01910.1016/j.ejca.2004.06.019 ↗
4. 10.3324/haematol.2014.11281310.3324/haematol.2014.112813 ↗
5. 10.1016/j.critrevonc.2019.10283710.1016/j.critrevonc.2019.102837 ↗
6. Anand S. · Clin Adv. Hematol. Oncol. · 2020 · 18 · 640
7. 10.1016/j.molmed.2017.03.00110.1016/j.molmed.2017.03.001 ↗
8. 10.1182/blood-2005-01-016010.1182/blood-2005-01-0160 ↗
9. 10.1155/2017/602730510.1155/2017/6027305 ↗
10. 10.1172/JCI20042094510.1172/JCI200420945 ↗
11. 10.1182/asheducation-2008.1.15910.1182/asheducation-2008.1.159 ↗
12. 10.1126/science.110474210.1126/science.1104742 ↗
13. 10.1056/NEJMra180428110.1056/NEJMra1804281 ↗
14. 10.1016/j.smim.2014.01.00110.1016/j.smim.2014.01.001 ↗
15. 10.1177/1759720X1879846210.1177/1759720X18798462 ↗
16. 10.2146/ajhp07044910.2146/ajhp070449 ↗
17. 10.1016/j.intimp.2005.05.01010.1016/j.intimp.2005.05.010 ↗
18. 10.1007/s00296-009-1075-410.1007/s00296-009-1075-4 ↗
19. 10.1021/acsami.6b1340610.1021/acsami.6b13406 ↗
20. 10.1002/jat.349910.1002/jat.3499 ↗
21. 10.1016/j.jconrel.2016.01.02010.1016/j.jconrel.2016.01.020 ↗
22. 10.1093/nsr/nwaa22610.1093/nsr/nwaa226 ↗
23. 10.1039/C7BM00769H10.1039/C7BM00769H ↗
24. 10.17113/ftb.57.02.19.583210.17113/ftb.57.02.19.5832 ↗
25. 10.1021/acsnano.9b0567910.1021/acsnano.9b05679 ↗
26. 10.1021/acs.nanolett.7b0526310.1021/acs.nanolett.7b05263 ↗
27. 10.1080/17435390.2020.177178510.1080/17435390.2020.1771785 ↗
28. 10.1007/s00204-009-0488-x10.1007/s00204-009-0488-x ↗
29. 10.17113/ftb.57.02.19.583210.17113/ftb.57.02.19.5832 ↗
30. 10.3109/17435390.2012.76300110.3109/17435390.2012.763001 ↗
31. 10.3324/haematol.2018.20987410.3324/haematol.2018.209874 ↗
32. 10.1038/nrclinonc.2018.810.1038/nrclinonc.2018.8 ↗
33. 10.3390/ijms1906180110.3390/ijms19061801 ↗
34. 10.1371/journal.pone.023261210.1371/journal.pone.0232612 ↗
35. 10.1097/MD.000000000000315010.1097/MD.0000000000003150 ↗
36. 10.1016/j.gene.2012.09.06010.1016/j.gene.2012.09.060 ↗
37. 10.18632/oncotarget.657010.18632/oncotarget.6570 ↗
38. 10.7150/ntno.2571910.7150/ntno.25719 ↗
39. 10.1021/acs.nanolett.9b0212710.1021/acs.nanolett.9b02127 ↗
40. 10.1016/j.scib.2019.04.01710.1016/j.scib.2019.04.017 ↗
41. 10.1038/nrclinonc.2018.810.1038/nrclinonc.2018.8 ↗
42. 10.1182/blood-2013-08-52141910.1182/blood-2013-08-521419 ↗
43. 10.1002/ijc.2944510.1002/ijc.29445 ↗
44. 10.1172/jci.insight.9624410.1172/jci.insight.96244 ↗
45. 10.1016/j.metabol.2018.01.00210.1016/j.metabol.2018.01.002 ↗
46. 10.1038/srep0119610.1038/srep01196 ↗